Connect with us

Technology

SOPHiA GENETICS and Genomenon Collaborate to Streamline Genetic Research

Published

on

The companies expand partnership to enhance genetic variant interpretation for cancers and rare diseases

BOSTON and ROLLE, Switzerland , Nov. 6, 2024 /PRNewswire-PRWeb/ — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s Mastermind® Genomic Intelligence Platform into SOPHiA GENETICS’ Alamut™ Visual Plus, to empower researchers and clinical geneticists with a solution that helps accelerate variant interpretation for rare disorders.

Time is crucial in gathering actionable insights for rare diseases and cancers due to the complexity and unknown elements of their genetic underpinnings. Identifying these variants often involves navigating limited literature and sparse data, as many rare disorders lack comprehensive studies. Delays in finding relevant information can hinder accurate analysis and interpretation of genomic variants. Many rare conditions have no cure, and easy access to relevant, comprehensive and well-organized information can help accelerate insights and health decisions.

Alamut™ Visual Plus is an advanced decision-support tool for the exploration, annotation, and interpretation of genetic variants from next-generation sequencing (NGS) data. Genomenon’s Mastermind® Genomic Intelligence Platform provides comprehensive curated evidence for genomic data, as well an indexed content from more than 10 million full-text articles. The integration of the two tools significantly enhances variant curation and interpretation by connecting the Alamut™ Visual Plus comprehensive, full genome browser for variant interpretation to a vast library of scientific research, offering critical insights even for rare variants with limited existing research. This partnership will prove especially valuable in such cases where findings from only a single study globally might be available that hold the key to understanding a variant’s pathogenicity. By offering immediate access to a broad spectrum of indexed data and curated genomic insights, researchers and clinicians can more efficiently assess the pathogenicity of variants, enabling them to make informed decisions with greater confidence.

“We are excited to expand our work with Genomenon and provide our customers the opportunity to access world-class tools like Mastermind® through our technology platform.” said Ross Muken, President, SOPHiA GENETICS. “This partnership simultaneously benefits our customers, who will gain a more comprehensive understanding of detected variants in a seamless, single platform, while providing Genomenon the opportunity to broaden its reach through our unmatched global network.”

“Collaborating with SOPHiA GENETICS allows us to provide geneticists and researchers with the most comprehensive and up-to-date genomic research available as they review patient data in Alamut,” said Mike Klein, CEO of Genomenon. “The links to Mastermind® from Alamut will put curated genomic data and the most recent research on every variant at the fingertips of clinicians assure patient diagnoses are informed by the most recent scientific findings in a single, complete workflow.”

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.

About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

About Genomenon
Genomenon is a leading genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world’s premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights. Genomenon’s integrated software, data, and services solutions empower clients with advanced patient diagnosis and precision medicine development. For more information, visit GENOMENON.COM.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

SOPHiA GENETICS Media Contact:
Kelly Katapodis
media@sophiagenetics.com

Genomenon Media Contact:
Colleen McMillen
cmcmillen@genomenon.com

Media Contact

Colleen McMillen, https://www.genomenon.com, 9173449360, cmcmillen@genomenon.com, https://www.genomenon.com

Twitter

View original content to download multimedia:https://www.prweb.com/releases/sophia-genetics-and-genomenon-collaborate-to-streamline-genetic-research-302297017.html

SOURCE Genomenon

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Oberon Securities Advises Keens Steakhouse in Sale Transaction

Published

on

By

Oberon Securities acted as exclusive advisor to Keens Steakhouse in the sale transaction.

NEW YORK, Nov. 23, 2024 /PRNewswire-PRWeb/ — Oberon Securities, a New York-based middle market investment banking firm, acted as exclusive advisor to Keens Steakhouse in the sale transaction announced yesterday.

With more than 70 senior bankers serving businesses across the country and around the world, Oberon is one of the fastest growing New York City based middle-market investment banking firms. Its clients benefit from the market credibility associated with the firm’s longstanding relationships with many of the nation’s largest and most prestigious institutional investors. Oberon’s approach has generated numerous long-term, multi-transaction client engagements and attracted investment bankers who have spent their careers working with middle-market companies.

Media Contact

Steven Alschuler, Oberon Securities, 1 917-647-2151, steve@alschulerpr.com, https://oberonsecurities.com/

View original content to download multimedia:https://www.prweb.com/releases/oberon-securities-advises-keens-steakhouse-in-sale-transaction-302314708.html

SOURCE Oberon Securities; Oberon Securities

Continue Reading

Technology

Specified Technologies Inc. Unveils Firestop Clash Management and Locator Updates

Published

on

By

SOMERVILLE, N.J., Nov. 23, 2024 /PRNewswire/ — Specified Technologies Inc. has announced their latest Firestop Clash Management (FCM) and Firestop Locator (FSL) releases. FCM automates the process of locating and assigning firestop solutions to conditions within Autodesk® Revit®, enabling firestop novices to find firestop solutions like a firestop expert. In this latest release, STI has further expanded the capabilities of FCM by integrating it with their firestop documentation and compliance tool, Firestop Locator (FSL). FSL enables contractors and facilities’ teams to document the status, location, and products used for any and all fire life safety services across a building.

In the latest update for FSL, teams can now create custom items to track any service on their project beyond the base six (Penetration, Joint, Extinguisher, Door, Damper, and Barrier). Teams can also modify the base six items to include project specific inspection and maintenance requirements and any other details that they would like to be tracked.

With this new integration, decisions made during the design phase of a building using FCM are seamlessly passed into FSL during the construction phase, giving implementation teams a jump start on work to be done. This integration also improves data integrity and eliminates the guesswork in the field of determining what firestop systems and products are to be used where.

“We’re proud of the latest releases of FCM and FSL and look forward to continuing to support the fire life safety community,” says Justin Pine, Sr. Manager of Software & Services.

Specified Technologies Inc. promotes life and building safety by developing innovative fire protection systems and accompanying digital tools that help stop the spread of fire, smoke, and hot gases. Our SpecSeal® and EZ Path® product lines are engineered for easy installation and deliver powerful performance, often resulting in lower installed costs. Since firestopping is our only business, we concentrate all our resources on providing the highest quality, fully tested, innovative firestopping solutions.

Contact: Jess Bern; jbern@stifirestop.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/specified-technologies-inc-unveils-firestop-clash-management-and-locator-updates-302314629.html

SOURCE Specified Technologies, Inc.

Continue Reading

Technology

ZICC: Internet Experts Pay Attention to the Development of Artificial Intelligence

Published

on

By

BEIJING, Nov. 23, 2024 /CNW/ — During the Wuzhen Summit of the World Internet Conference, ZICC interviewed Internet experts from all over the world.

Lampros Sterg, UNESCO Chair in AI & Data Science, said that AI can accelerate social progress, but it needs to be used properly to avoid its negative effects in order to benefit citizens and society. Latif Ladid, the president of the IPv6 Forum, called for the establishment of a global governance system to allow artificial intelligence technology to serve humanity for good. South Korean computer scientist Kilnam Chon shared insights on AI’s positive role in healthcare. He urged global efforts to ensure AI safety and prevent its misuse in weapons. Indian entrepreneur Bibin Babu said he believes that AI will not replace humans, but will create more new jobs.

View original content to download multimedia:https://www.prnewswire.com/news-releases/zicc-internet-experts-pay-attention-to-the-development-of-artificial-intelligence-302314745.html

SOURCE ZICC

Continue Reading

Trending